Challenging resistance mechanisms to therapies for metastatic melanoma

Trends in Pharmacological Sciences

Volumn 34, Issue 12, 2013, Pages 656-666

  Tentori, Lucio ^a   Lacal, Pedro Miguel ^b   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

BRAF inhibitors; immunotherapy; ipilimumab; poly(ADP ribose) polymerase (PARP) inhibitors; temozolomide; vemurafenib

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ARRY 438162; BEVACIZUMAB; BORTEZOMIB; BUPARLISIB; COBIMETINIB; CP 870893; DABRAFENIB; DACARBAZINE; EVEROLIMUS; GLYCOPROTEIN GP 100; INO 1001; INTERLEUKIN 2; IPILIMUMAB; LAMBROLIZUMAB; LOMEGUATRIB; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NIVOLUMAB; OBLIMERSEN; OLAPARIB; PLACEBO; RUCAPARIB; SUNITINIB; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; UNINDEXED DRUG; VELIPARIB; VEMURAFENIB;

BONE MARROW TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; GLIOBLASTOMA; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; LONG TERM SURVIVAL; MELANOMA CELL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR ESCAPE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

BRAF INHIBITORS; IMMUNOTHERAPY; IPILIMUMAB; POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS; TEMOZOLOMIDE; VEMURAFENIB;

ANTIBODIES, MONOCLONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; INDOLES; MELANOMA; NEOPLASM METASTASIS; OXIMES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84889091074     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.10.003     Document Type: Review

References (86)

1. E. Fonkem Melanoma brain metastasis: overview of current management and emerging targeted therapies Expert Rev. Neurother. 12 2012 1207 1215
2. P.M. Patel Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032) Eur. J. Cancer 47 2011 1476 1483
3. R.F. Kefford A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma Br. J. Cancer 100 2009 1245 1249
4. H.A. Tawbi Inhibition of DNA repair with MGMT pseudosubstrates: Phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours Br. J.Cancer 105 2011 773 777
5. J.C. Hassel MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome Br. J. Cancer 103 2010 820 826
6. W.P. Roos Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid Cancer Res. 71 2011 4150 4160
7. L. Tentori The glutathione transferase inhibitor 6-(7-nitro-2,1,3- benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma Eur. J. Cancer 47 2011 1219 1230
8. C. Barckhausen Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair Oncogene 2013 10.1038/onc.2013.141
9. T. Sinnberg Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide J. Invest. Dermatol. 129 2009 1500 1515
10. R.S. Dronca Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675 Am. J. Clin. Oncol. 2013 10.1097/COC.0b013e31827b45d4
11. S. Caporali NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug J. Transl. Med. 10 2012 252
12. L. Levati Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB Int. J. Oncol. 38 2011 241 247
13. M. De Vos The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art Biochem. Pharmacol. 84 2012 137 146
14. L. Tentori, and G. Graziani Recent approaches to improve the antitumor efficacy of temozolomide Curr. Med. Chem. 16 2009 245 257
15. L. Tentori Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent Curr. Cancer Drug Targets 10 2010 368 383
16. H. Toshimitsu Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma Ann. Surg. Oncol. 17 2010 2247 2254
17. A.Y. Bedikian A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma Cancer Invest. 27 2009 756 763
18. O.A. Khan A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours Br. J. Cancer 104 2011 750 755
19. Anon. (2011) Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant. Oncology (Williston Park) 15, 1213, 1232
20. R. Plummer A Phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation Cancer Chemother. Pharmacol. 71 2013 1191 1199
21. L.V. Kalialis Spontaneous regression of metastases from melanoma: review of the literature Melanoma Res. 19 2009 275 282
22. M. Maio Melanoma as a model tumour for immuno-oncology Ann. Oncol. 23 Suppl. 8 2012 10 14
23. T.K. Eigentler A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma Clin. Cancer Res. 17 2011 7732 7742
24. F.S. Hodi Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 2010 711 723
25. D.J. Schwartzentruber gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N. Engl. J. Med. 364 2011 2119 2127
26. C. Robert Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N. Engl. J. Med. 364 2011 2517 2526
27. K. Margolin Ipilimumab in a Phase II trial of melanoma patients with brain metastases Oncoimmunology 1 2012 1197 1199
28. B. Sherrill Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma Br. J. Cancer 109 2013 8 13
29. J.D. Wolchok Four-year survival rates for patients with metastatic melanoma who received ipilimumab in Phase II clinical trials Ann. Oncol. 24 2013 2174 2180
30. A. Ribas Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J. Clin. Oncol. 31 2013 616 622
31. D.T. Frederick BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma Clin. Cancer Res. 19 2013 1225 1231
32. O. Hamid Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144
33. J.L. Riley Combination checkpoint blockade - taking melanoma immunotherapy to the next level N. Engl. J. Med. 369 2013 187 189
34. J.D. Wolchok Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 2013 122 133
35. J.R. Brahmer Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 2012 2455 2465
36. R.H. Vonderheide Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody J. Clin. Oncol. 25 2007 876 883
37. K. Schwager The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF J. Invest. Dermatol. 133 2013 751 758
38. R.B. Holmgaard Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 J. Exp. Med. 210 2013 1389 1402
39. K. Trunzer Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma J. Clin. Oncol. 31 2013 1767 1774
40. P.B. Chapman Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
41. J.A. Sosman Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N. Engl. J. Med. 366 2012 707 714
42. A. Hauschild Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial Lancet 380 2012 358 365
43. G.S. Falchook Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase 1 dose-escalation trial Lancet 379 2012 1893 1901
44. R.K. Mittapalli Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases J. Pharmacol. Exp. Ther. 344 2013 655 664
45. A.E. Aplin Mechanisms of resistance to RAF inhibitors in melanoma J. Invest. Dermatol. 131 2011 1817 1820
46. M. Banaszynski Vemurafenib and ipilimumab: new agents for metastatic melanoma Am. J. Health Syst. Pharm. 70 2013 1205 1210
47. E. Romano Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression Clin. Cancer Res. 2013 10.1158/1078-0432.CCR-13- 0661
48. R.J. Sullivan, and K.T. Flaherty Resistance to BRAF-targeted therapy in melanoma Eur. J. Cancer 49 2013 1297 1304
49. P.I. Poulikakos RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
50. F. Su RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N. Engl. J. Med. 366 2012 207 215
51. M.K. Callahan Progression of RAS-mutant leukemia during RAF inhibitor treatment N. Engl. J. Med. 367 2012 2316 2321
52. L. Zimmer Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition Clin. Oncol. 30 2012 2375 2383
53. J.G. Greger Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations Mol. Cancer Ther. 11 2012 909 920
54. H. Shi Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat. Commun. 3 2012 724
55. P.I. Poulikakos RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387 390
56. C.M. Johannessen COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
57. R. Straussman Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 2012 500 504
58. K.L. Nathanson tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436) Clin. Cancer Res. 19 2013 4868 4878
59. K.S. Smalley Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas Mol. Cancer Ther. 7 2008 2876 2883
60. C.P. Wu Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells Biochem. Pharmacol. 85 2013 325 334
61. K.T. Flaherty Improved survival with MEK inhibition in BRAF-mutated melanoma N. Engl. J. Med. 367 2012 107 114
62. K.T. Flaherty Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N. Engl. J. Med. 367 2012 1694 1703
63. K.B. Kim Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor J. Clin. Oncol. 31 2013 482 489
64. J.M. Kirkwood Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma Clin. Cancer Res. 18 2012 555 567
65. C. Robert Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a Phase 2 double-blind randomised study Lancet Oncol. 14 2013 733 740
66. S. Patel Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma Cancer 119 2013 799 805
67. S.A. Byron Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wild type PTEN status Mol. Cancer 2012 10.1186/1476-4598-11-75
68. O.K. Mirzoeva Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition Cancer Res. 69 2009 565 572
69. F. Catalanotti Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma Clin. Cancer Res. 19 2013 2257 2264
70. T. Shimizu The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer Clin. Cancer Res. 18 2012 2316 2325
71. H. Shi Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition Cancer Res. 71 2011 5067 5074
72. B. Chen BRAFV600E negatively regulates the AKT pathway in melanoma cell lines PLoS ONE 7 2012 e42598
73. M. Das Thakur Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255
74. M.S. Carlino Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma Mol. Cancer Ther. 12 2013 1332 1342
75. D.G. Coit Melanoma, version 2.2013: featured updates to the NCCN guidelines J. Natl. Compr. Canc. Netw. 11 2013 395 407
76. F.S. Hodi Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin J. Clin. Oncol. 31 2013 3182 3190
77. J.R. Todd Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells Pigment Cell Melanoma Res. 26 2013 518 526
78. J. Schlegel MERTK receptor tyrosine kinase is a therapeutic target in melanoma J. Clin. Invest. 123 2013 2257 2267
79. F. Ruffini Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms Int. J. Oncol. 43 2013 297 306
80. A. Sharma Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors Cancer Res. 65 2005 2412 2421
81. C.L. Slingluff Jr Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a Phase II trial (CTEP 7190/Mel47) Clin. Cancer Res. 19 2013 3611 3620
82. R. von Moos First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07) Ann. Oncol. 23 2012 531 536
83. L.A. Kottschade A randomized Phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775 Cancer 119 2013 586 592
84. M. Eich Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide Mol. Cancer Ther. 2013 10.1158/1535-7163.MCT-13-0136
85. D. Schadendorf Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [abstract]. Eur. Cancer Congress 2013 LBA24 in Ipilimumab-treated patients survive up to 10 years Nat. Rev. Clin. Oncol. 2013 10.1038/nrclinonc.2013.191
86. P.A. Ascierto MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Lancet Oncol. 14 2013 249 256